DOI QR코드

DOI QR Code

Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

  • Uchino, Junji ;
  • Hirano, Ryosuke ;
  • Tashiro, Naoki ;
  • Yoshida, Yuji ;
  • Ushijima, Shinichiro ;
  • Matsumoto, Takemasa ;
  • Ohta, Keiichi ;
  • Nakatomi, Keita ;
  • Takayama, Koichi ;
  • Fujita, Masaki ;
  • Nakanishi, Yoichi ;
  • Watanabe, Kentaro
  • Published : 2012.08.31

Abstract

Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.

Keywords

CINV;aprepitant;complete suppression rate of nausea;food intake

References

  1. Andrykowski MA (1988). Defining anticipatory nausea and vomiting: differences among cancer chemotherapy patients who report pretreatment nausea. J Behav Med, 11, 59-69. https://doi.org/10.1007/BF00846169
  2. Basch E, Prestrud AA, Hesketh PJ, et al (2011). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 29, 4189-98. https://doi.org/10.1200/JCO.2010.34.4614
  3. de Wit R, Herrstedt J, Rapoport B, et al (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer, 40, 403-10.
  4. Ettinger DS, Bierman PJ, Bradbury B, et al (2007). Antiemesis. J Natl Compr Canc Netw, 5, 12-33. https://doi.org/10.6004/jnccn.2007.0004
  5. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  6. Huskey SE, Dean BJ, Bakhtiar R, et al (2003). Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos, 31, 785-91. https://doi.org/10.1124/dmd.31.6.785
  7. Jordan K, Hinke A, Grothey A, et al (2007). A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15, 1023-33. https://doi.org/10.1007/s00520-006-0186-7
  8. Kris MG, Hesketh PJ, Somerfield MR, et al (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol, 24, 2932-47. https://doi.org/10.1200/JCO.2006.06.9591
  9. Morrow GR, Lindke J, Black PM (1991). Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage, 6, 215-23. https://doi.org/10.1016/0885-3924(91)90011-R
  10. Morrow GR, Morrell C (1982). Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med, 307, 1476-80. https://doi.org/10.1056/NEJM198212093072402
  11. Navari RM (2009a). Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother, 10, 629-44. https://doi.org/10.1517/14656560902731894
  12. Navari RM (2009b). Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs, 69, 515-33. https://doi.org/10.2165/00003495-200969050-00002
  13. Perez EA, Hesketh P, Sandbach J, et al (1998). Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol, 16, 754-60. https://doi.org/10.1200/JCO.1998.16.2.754
  14. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8. https://doi.org/10.1002/cncr.11433
  15. Rapoport BL, Jordan K, Boice JA, et al (2010). Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer, 18, 423-31. https://doi.org/10.1007/s00520-009-0680-9
  16. Richardson JL, Marks G, Levine A (1988). The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol, 6, 1746-52. https://doi.org/10.1200/JCO.1988.6.11.1746
  17. Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, v232-43. https://doi.org/10.1093/annonc/mdq194
  18. Rojas C, Stathis M, Thomas AG, et al (2008). Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg, 107, 469-78. https://doi.org/10.1213/ane.0b013e318172fa74
  19. Saito M, Aogi K, Sekine I, et al (2009). Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol, 10, 115-24. https://doi.org/10.1016/S1470-2045(08)70313-9
  20. Takeuchi H, Saeki T (2010). An antiemetic guideline for patients with malignancies in Japan. Gan To Kagaku Ryoho, 37, 976-9 (in Japanese).
  21. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006). Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94, 1011-5. https://doi.org/10.1038/sj.bjc.6603048
  22. Wong EH, Clark R, Leung E, et al (1995). The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol, 114, 851-9. https://doi.org/10.1111/j.1476-5381.1995.tb13282.x

Cited by

  1. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan vol.22, pp.7, 2014, https://doi.org/10.1007/s00520-014-2146-y
  2. Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10045
  3. Substance P is a Major Mediator Causing Delayed Emesis in Anthracycline-Based Chemotherapy - Really? vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10993
  4. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy vol.23, pp.1, 2015, https://doi.org/10.1007/s00520-014-2339-4
  5. Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3350